Never Give Up: Amarin Will Appeal Latest Vascepa Patent Loss
Company Still Sees Profit Potential Even With US Generic Competitors
Executive Summary
A Federal Circuit panel affirmed a district court decision in favor of two generics makers, but Amarin will seek a hearing from the full 12-member appellate court. Vascepa marketing is unchanged for now.
You may also be interested in...
Amarin Steps Closer To EU Cardiovascular Risk Market
The European Medicines Agency has recommended in favor of approval for Amarin’s fish-oil derivative, Vazkepa.
Amarin Builds Sales Infrastructure For EU Vazkepa Launch
With an approval nod from the EMA’s scientific committee for its fish oil product Vazkepa, launch plans for the EU for this “multi-billion dollar” opportunity are on track, says Amarin CEO.
Moment Of Truth In EU For Amarin’s ‘Multi-Billion-Dollar Opportunity’ Drug
The European Medicines Agency is expected to decide soon whether Amarin’s fish oil pill, Vascepa, should win pan-EU marketing approval for reducing cardiovascular risk.